Cholesterol lowering and endothelial function

American Journal of Medicine

Volumn 107, Issue 5, 1999, Pages 479-487

  Vogel, Robert A ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BEZAFIBRATE; COLESTYRAMINE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; DIET SUPPLEMENTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 0033230531     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00261-2     Document Type: Review

References (123)

1. Risk factors and coronary heart disease. A statement for physicians. Circulation. 62:1980;449A-455A.
2. Anderson M., Castelli W.P., Levy D. Cholesterol and mortality 30 years of follow-up from the Framingham Study . JAMA. 257:1987;2176-2180.
3. The Lipid Research Clinics Coronary Primary Prevention Trial Result. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
4. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. NEJM. 317:1987;1237-1245.
5. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypothesis of the trial. JAMA. 263:1990;1795-1801.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
7. Sachs F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. NEJM. 335:1996;1001-1009.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEJM. 339:1998;1349-1357.
9. Downs J.R., Clearfield M., Whitney E., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
10. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 333:1995;1301-1307.
11. Ross R. The pathogenesis of atherosclerosis. NEJM. 314:1986;488-500.
12. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. NEJM. 320:1989;915-924.
13. Gordon D., Reidy M.A., Benditt E.P., Schwartz S.M. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA. 87:1990;4600-4604.
14. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease. NEJM. 326:1992;242-250.
15. Ross R. Atherosclerosis - an inflammatory disease. NEJM. 340:1998;115-126.
16. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
17. Davies P.F., Dewey C.F., Bussolari S.R., et al. Influence of hemodynamic forces on vascular endothelial function in vitro studies of shear stress and pinocytosis in bovine aortic cells . J Clin Invest. 73:1984;1121-1129.
18. Frangos J.A., Eskin S.G., McIntire L.V., Ives C.L. Flow effects on prostacyclin production by cultured human endothelial cells. Science. 227:1985;1477-1479.
19. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. NEJM. 315:1986;1046-1051.
20. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
21. Werns S.W., Walton J.A., Hsia H.H., et al. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation. 79:1989;287-291.
22. Springer T.A. Adhesion receptors of the immune system. Nature. 346:1990;425-434.
23. Dzau V.J., Gibbons G.H., Cooke J.P., Omoigui N. Vascular biology and medicine in the 1990's. Scope concepts, potentials, and perspectives . Circulation. 87:1993;705-719.
24. Vogel R.A., Corretti M.C., Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis. 41:1998;117-136.
25. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. NEJM. 330:1994;1431-1438.
26. Vogel R.A. Coronary risk factors, endothelial function, and atherosclerosis a review . Clin Cardiol. 20:1997;426-432.
27. Celermajer D.S. Endothelial dysfunction Does it matter? Is it reversible? J Am Coll Cardiol. 30:1997;325-333.
28. The Lipid Research Clinics Coronary Primary Prevention Trial Result. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
29. Verschuren W.M.M., Jacobs D.R., Bloemberg B.P.M., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the Seven Countries Study. JAMA. 274:1995;131-136.
30. Fuster V., Steele P.M., Chesebro J.H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 5:1986;175B-184B.
31. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
32. Farb A., Burke A.P., Tang A.L., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
33. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
34. Levine G.N., Keaney J.F. Jr, Vita J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. NEJM. 332:1995;512-521.
35. Gimbrone M.A. Jr, Bevilacqua M.P., Cubulsky M.I. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann NY Acad Sci. 598:1990;77-85.
36. Lerman A., Hildebrand F.L. Jr, Margulies K.B., et al. Endothelin a new cardiovascular regulatory peptide . Mayo Clin Proc. 65:1990;1441-1455.
37. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550.
38. Creager M.A., Gallagher S.J., Girerd X.J., et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
39. Mocada S., Higgs A. The L-arginine-nitric oxide pathway. NEJM. 329:1993;2002-2012.
40. Harrison D.G. Nitric oxide and nitric oxide synthases. J Clin Invest. 100:1997;2153-2157.
41. Kugiyama K., Kerns S.A., Morisett J.D., et al. Impairment of endothelium-dependent-relaxation by lysolecithin in modified low-density lipoproteins. Nature. 334:1990;160-162.
42. Chin J.H., Azhan S., Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 89:1992;10-18.
43. Chen L.Y., Mehta P., Mehta J.L. Oxidized LDL decreases L-arginine uptake and nitric oxide protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function. Circulation. 93:1996;1740-1746.
44. Superko H.R. Beyond LDL cholesterol reduction. Circulation. 94:1996;2351-2354.
45. Scanu A.M., Lawn R.M., Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 115:1991;209-218.
46. Vogel R.A., Corretti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 79:1997;350-354.
47. Lundman P., Eriksson M., Schenck-Gustafsson K., et al. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 96:1997;3266-3268.
48. Mano T., Masuyama T., Yamamoto K., et al. Endothelial dysfunction in the early stage precedes appearance of intimal lesions assessable with intravascular ultrasound. Am Heart J. 131:1996;231-238.
49. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor responses to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
50. Seiler C., Hess M., Buechi M., et al. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 88:(pt 1):1993;2139-2148.
51. Panza J.A., Casino P.R., Kilcoyne C.M., et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 87:1993;1468-1474.
52. Glasser S.P., Selwyn A.P., Ganz P. Atherosclerosis risk factors and the vascular endothelium . Am Heart J. 131:1996;379-384.
53. Celermajer D.S., Sorensen K.E., Bull C., et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 24:1994;1468-1474.
54. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. NEJM. 332:1995;488-493.
55. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEJM. 332:1995;481-487.
56. Stroes E.S.G., Koomans H.A., de Bruin T.W.A., et al. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
57. Shimokawa A.H., Vanhoutte P.M. Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. J Am Coll Cardiol. 13:1989;1402-1408.
58. Simon B.C., Cunningham L.D., Cohen R.A. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 86:1990;75-79.
59. Matsuda Y., Hirata K., Inoue N., et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 72:1993;1103-1109.
60. Casino P.R., Kilcoyne C.M., Quyyumi A.A., et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 88:1993;2541-2547.
61. Creager M.A., Selwyn A. When normal cholesterol levels injure the endothelium. Circulation. 96:1997;3255-3257.
62. Osborne J.A., Lento P.H., Siegfried M.R., et al. Cardiovascular effects of acute hypercholesterolemia. Reversal with lovastatin treatment. J Clin Invest. 83:1989;465-473.
63. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
64. Galle J., Bengen J., Schollmeyer P., Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation. 92:1995;1582-1589.
65. Raitakari O.T., Pitkanen O.-P., Lehtimaki T., et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol. 30:1997;97-102.
66. Hacknman A., Abe Y., Insull W., et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation. 93:1996;1334-1338.
67. Sampietro T., Tuomi M., Ferdeghini M., et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familiar hypercholesterolemia. Circulation. 96:1997;1381-1385.
68. Lacoste L., Lam J.Y.T., Hung J., et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
69. Nofer J.-R., Tepel M., Kehrel B., et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation. 95:1997;1370-1377.
70. Flavahan N.A., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor. Blood Vessels. 27:1990;238-245.
71. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
72. Kuhn F.E., Mohler E.R., Reagan K., et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1425:1991;30.
73. Quyyumi A.A., Dakak N., Diodati J.G., et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 30:1997;1220-1227.
74. Chauhan A., More R.S., Mullins P.A., et al. Aging-associated endothelial dysfunction is reversed by L-arginine. J Am Coll Cardiol. 28:1996;1796-1804.
75. Casino P.R., Kilcoyne C.M., Quyyumi A.A., et al. Investigation of decreased availability of nitric oxide precursor as the mechanism for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. 23:1994;844-850.
76. Ohara Y., Pederson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide production. J Clin Invest. 91:1993;2546-2551.
77. Harrison D.G. Endothelial function and oxidative stress. Clin Cardiol. 20:(suppl II):1997;II11-II17.
78. Minor R. Jr, Myers P.R., Guerra R. Jr, et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 86:1990;2109-2116.
79. Gilligan D.M., Sack M.N., Guetta V., et al. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol. 24:1994;1611-1617.
80. Plotnick G.D., Corretti M.C., Vogel R.A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent vasoactivity following a single high-fat meal. JAMA. 278:1997;1682-1686.
81. Levine G.N., Frei B., Koulouris S.N., et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
82. Weber C., Erl W., Weber K., et al. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation. 93:1996;1488-1492.
83. Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 96:1997;1513-1519.
84. Garcia C.E., Kilcoyne C.M., Cardillo C., et al. Evidence that endothelial function in patients with hypercholesterolemia is not due to increased extracellular nitric oxide breakdown by superoxide anions. Am J Cardiol. 76:1995;1157-1161.
85. Walldius G., Erikson U., Olsson A.G., et al. The effect of probucol on femoral atherosclerosis the Probucol Quantitative Regression Trial (PQRST) . Am J Cardiol. 74:1994;875-883.
86. Luscher T.F., Barton M. Biology of the endothelium. Clin Cardiol. 20:(suppl II):1997;II3-II10.
87. Yanagisawa M. The endothelin system. A new target for theraputic intervention. Circulation. 89:1994;1320-1322.
88. Lerman A., Edwards B.S., Hallett J.W., et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. NEJM. 325:1991;997-1001.
89. Mathew V., Cannan C.R., Miller V.M., et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 96:1997;1930-1936.
90. Leung W.-H., Lau C.-P., Wong C.-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
91. Vogel R.A., Corretti M.C., Plotnick G.P. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol. 77:1996;37-40.
92. Seiler C., Suter T.M., Hess O.M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 26:1995;1615-1622.
93. Goode G.K., Heagerty A.M. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation. 91:1995;2898-2903.
94. Yeung A, Hodgson JM, Winniford M, et al. Assessment of coronary vascular reactivity after cholesterol lowering. Circulation 1996;94(suppl I):I402 Abstract.
95. Drury J, Cohen JD, Veenendrababu B, et al. Brachial artery endothelium dependent vasodilation in patients enrolled in the cholesterol and recurrent events (CARE) study. Circulation 1996;94(suppl I):I402 Abstract.
96. Tamai O., Matsuoka H., Itabe H., et al. Single LDL aphesesis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
97. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
98. Andrews T.C., Whitnet E.J., Green G., et al. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dL and high-density lipoprotein cholesterol levels <40 mg/dL. Am J Cardiol. 80:1997;831-835.
99. Vogel R.A., Corretti M.C., Plotnick G.D. The mechanism of improvement in endothelial function by pravastatin direct effect or through cholesterol lowering . J Am Coll Cardiol. 31:1998;60A.
100. John S., Schlaich M., Langenfeld M., et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, place-controlled, double-blind study. Circulation. 98:1998;211-216.
101. Steinberg H.O., Bayazeed B., Hook G.H., et al. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation. 96:1997;3287-3293.
102. Chen L., Haught W.H., Yang B., et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 30:1997;569-575.
103. Weber C., Erl W., Weber K.S.C., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 30:1997;1212-1217.
104. Gould K.L., Ornish D., Scherwitz L., et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA. 274:1995;894-901.
105. van Boven A.J., Jukema J.W., Zwinderman A.H., et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
106. Aengevaeren W.R.M., Uijen G.R.H., Jukema J.W., et al. Functional improvement by pravastatin in the regression growth evaluation statin study (REGRESS). Circulation. 96:1997;429-435.
107. Andrews T.C., Raby K., Barry J., et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
108. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1789.
109. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:1993;2762-2770.
110. Brown B.G., Maher V.M.G. Reversal of coronary heart disease by lipid-lowering therapy. Observations and pathological mechanisms. Circulation. 89:1994;2928-2933.
111. Davies M.J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 82:(suppl II):1990;II38-II46.
112. Jha P., Flather M., Lonn E., et al. The antoxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med. 123:1995;860-872.
113. Stephens N.G., Parsons A., Schofield P., et al. Randomised controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
114. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. NEJM. 330:1994;1029-1035.
115. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction results of the GISSI-Prevenzione trial . Lancet. 354:1999;447-455.
116. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Jr. Antioxidants and heart disease. NEJM. 337:1997;408-416.
117. Mosca L., Rubenfire M., Tarshis T., et al. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol. 80:1997;825-830.
118. Ohara Y., Peterson T.E., Sayegh H.S., et al. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation. 92:1995;898-903.
119. Mosca L, Rubenfire M, Mandel C, et al. Antioxidant nutrient supplementation reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary artery disease. J Am Coll Cardiol 1997;30:392-399.
120. Jilal I., Grundy S.M. Effect of combined supplementation with α-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation. 88:1993;2780-2786.
121. Neunteufl T., Kostner K., Katzenschlager R., et al. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol. 32:1998;711-716.
122. Elliott T.G., Barth J.D., Mancini G.B.J. Effects of vitamin E on endothelial function in men after myocardial infarction. Am J Cardiol. 76:1995;1188-1191.
123. Adams M.R., Jessup W., Celermajer D.S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells reversibility with oral L-arginine but not vitamin C . J Am Coll Cardiol. 29:1997;491-497.